DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline @ Gastrointestinal Stromal Tumors Pipeline Outlook

Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report

• On March 06, 2026- Deciphera Pharmaceuticals LLC announced a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
• On March 04, 2026- Bayer initiated a study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial.
• DelveInsight’s Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
• The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.

Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors @ Gastrointestinal Stromal Tumors Approved Drugs

The Gastrointestinal Stromal Tumors Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Gastrointestinal Stromal Tumors Pipeline Report also highlights the unmet needs with respect to the Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors Overview

Gastrointestinal Stromal Tumors (GIST) (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs

• Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

• Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

• THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

• DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline @ Gastrointestinal Stromal Tumors Treatment Drugs

The Gastrointestinal Stromal Tumors pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment.
• Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market.

Gastrointestinal Stromal Tumors Companies

Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Gastrointestinal Stromal Tumors Treatment @ Gastrointestinal Stromal Tumors Market Drivers and Barriers

Scope of the Gastrointestinal Stromal Tumors Pipeline Report

• Coverage- Global
• Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Famitinib: Jiangsu Hengrui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nilotinib: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS 6157: Daiichi Sankyo Company
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Gastrointestinal Stromal Tumors Key Companies
18. Gastrointestinal Stromal Tumors Key Products
19. Gastrointestinal Stromal Tumors- Unmet Needs
20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
22. Gastrointestinal Stromal Tumors Analyst Views
23. Gastrointestinal Stromal Tumors Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight